melatonin has been researched along with Metabolic Syndrome in 47 studies
Metabolic Syndrome: A cluster of symptoms that are risk factors for CARDIOVASCULAR DISEASES and TYPE 2 DIABETES MELLITUS. The major components of metabolic syndrome include ABDOMINAL OBESITY; atherogenic DYSLIPIDEMIA; HYPERTENSION; HYPERGLYCEMIA; INSULIN RESISTANCE; a proinflammatory state; and a prothrombotic (THROMBOSIS) state.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Out of the initial 41 studies, six documented five separate RCTs randomizing 248 patients (126 to melatonin/ramelteon, 122 to placebo) affected by schizophrenia-spectrum disorders and bipolar disorder." | 9.22 | Melatonin and melatonin-agonists for metabolic syndrome components in patients treated with antipsychotics: A systematic review and meta-analysis. ( Fornaro, M; Miola, A; Sambataro, F; Solmi, M, 2022) |
| "The incidence of dysmetabolic factors in 100 elderly patients with hypertension stage II and the role of melatoninproducing function of epiphysis (pineal gland) in the development of these disorders were studied." | 9.16 | [Metabolic disorders in elderly patients with hypertension and their correction with melatonin]. ( Antoniuk-Shcheglova, IA; Bondarenko, EV; Shatilo, VB, 2012) |
| "This systematic review and meta-analysis of randomized controlled trials (RCTs) was carried out to determine the effect of melatonin supplementation on the inflammatory markers among individuals with metabolic syndrome (MetS) and related disorders." | 8.98 | The effects of melatonin supplementation on inflammatory markers among patients with metabolic syndrome or related disorders: a systematic review and meta-analysis of randomized controlled trials. ( Akbari, M; Amirani, E; Asemi, Z; Heydari, ST; Lankarani, KB; Ostadmohammadi, V; Reiter, RJ; Tabrizi, R, 2018) |
| "Sprague-Dawley rats were divided into control (n = 8), melatonin (n = 8), metabolic syndrome (n = 8) and metabolic syndrome + melatonin (n = 8) groups." | 8.02 | Melatonin ameliorates cardiac remodelling in fructose-induced metabolic syndrome rat model by using genes encoding cardiac potassium ion channels. ( Ovali, MA; Oztopuz, O; Vardar, SA, 2021) |
| "The objective of this study was to evaluate the efficacy of melatonin to affect mild inflammation in the metabolic syndrome (MS) induced by a high-fat diet in rats." | 7.80 | Melatonin normalizes clinical and biochemical parameters of mild inflammation in diet-induced metabolic syndrome in rats. ( Cano Barquilla, P; Cardinali, DP; Esquifino, AI; Fernández-Mateos, P; Jiménez-Ortega, V; Pagano, ES, 2014) |
| "Effect of light regimens (standard 12:12 light/dark, constant light, natural lightning of the north-west of Russia) and that of melatonin on the development of metabolic syndrome during aging of rats was studied." | 7.79 | Melatonin prevents the development of the metabolic syndrome in male rats exposed to different light/dark regimens. ( Anisimov, V; Vinogradova, I, 2013) |
| " The patients presenting with metabolic syndrome are characterized by the interrelation between melatonin hypersecretion, parameters of hyperactivity of the sympathetic component of the nervous system, and prognostically unfavourable variants of cardiac and vascular remodeling (including endothelial dysfunction, concentric remodeling and concentric myocardial ventricular hypertrophy)." | 7.78 | [Melatonin as a marker of intensity of structural and functional changes in the heart and vessels of the patients presenting with metabolic syndrome]. ( Balliuzek, MF; Grinenko, TN; Kvetnaia, TV, 2012) |
| "In this study, we examined whether melatonin improves metabolic syndrome induced by high fructose intake in male Wistar rats." | 7.78 | Melatonin improves metabolic syndrome induced by high fructose intake in rats. ( Kitagawa, A; Ohashi, K; Ohta, Y, 2012) |
| "Melatonin, leptin, and insulin secretion was studied in 25 men with metabolic syndrome (MS) verified against IDF criteria (2005) (mean age 44 +/- 2 yr)." | 7.77 | [Relationship between insulin, leptin, and melatonin contents in patients with metabolic syndrome]. ( , 2011) |
| "The level of 6-oxymelatonin sulfate, the main metabolite of melatonin (MT), in morning urine samples from patients with metabolic syndrome (MS) suggests enhanced MT production at night." | 7.75 | [The role of melatonin in the development of metabolic syndrome]. ( Balliuzek, MF; Grinenko, TN; Kvetnaia, TV, 2009) |
| "Melatonin secretion decreased in fructose fed rats that developed hypertension." | 7.74 | The role of melatonin in the pathogenesis of hypertension in rats with metabolic syndrome. ( Grossman, E; Leibowitz, A; Peleg, E; Shabtai, Z; Shamiss, A; Sharabi, Y, 2008) |
| "The interrelations between testosterone, insulin and melatonin levels in males with metabolic syndrome (MS) are still not clarified, especially in young age groups." | 7.73 | Low testosterone levels and unimpaired melatonin secretion in young males with metabolic syndrome. ( Kirilov, G; Kumanov, P; Robeva, R; Tomova, A, 2006) |
| "Obesity is associated with an oxidative stress status, defined as an excessive production of reactive oxygen species (ROS) compared to the level of antioxidants acting in the natural defence systems." | 6.50 | Obesity and oxidative stress: potential roles of melatonin as antioxidant and metabolic regulator. ( Bonnefont-Rousselot, D, 2014) |
| "Melatonin has been suggested to be effective in improving MetS through its anti-hyperlipidemic action." | 6.49 | Metabolic syndrome, its pathophysiology and the role of melatonin. ( Espino, J; Mohamed, M; Ohta, Y; Pariente, JA; Rodriguez, AB; Srinivasan, V; Zakaria, R, 2013) |
| "Melatonin has specific MT1 and MT2 receptors localized in all body cells." | 6.49 | [Metabolic syndrome and melatonin]. ( Burlakova, OV; Golichenkov, VA; Molchanov, AIu; Rapoport, SI; Savchenko, ES; Suprunenko, ES, 2013) |
| "Melatonin has been shown to have beneficial effects in cardiovascular disorders including ischaemic heart disease and hypertension." | 6.48 | Melatonin and the metabolic syndrome: a tool for effective therapy in obesity-associated abnormalities? ( du Toit, EF; Lochner, A; Nduhirabandi, F, 2012) |
| "Obesity has become an epidemic in industrialized and developing countries." | 6.48 | Obesity and metabolic syndrome: association with chronodisruption, sleep deprivation, and melatonin suppression. ( Korkmaz, A; Ma, S; Reiter, RJ; Tan, DX, 2012) |
| "Melatonin is an effective chronobiotic agent able to change the phase and amplitude of circadian rhythms." | 6.47 | Melatonin and the metabolic syndrome: physiopathologic and therapeutical implications. ( Cano, P; Cardinali, DP; Esquifino, AI; Jiménez-Ortega, V, 2011) |
| "Out of the initial 41 studies, six documented five separate RCTs randomizing 248 patients (126 to melatonin/ramelteon, 122 to placebo) affected by schizophrenia-spectrum disorders and bipolar disorder." | 5.22 | Melatonin and melatonin-agonists for metabolic syndrome components in patients treated with antipsychotics: A systematic review and meta-analysis. ( Fornaro, M; Miola, A; Sambataro, F; Solmi, M, 2022) |
| "The incidence of dysmetabolic factors in 100 elderly patients with hypertension stage II and the role of melatoninproducing function of epiphysis (pineal gland) in the development of these disorders were studied." | 5.16 | [Metabolic disorders in elderly patients with hypertension and their correction with melatonin]. ( Antoniuk-Shcheglova, IA; Bondarenko, EV; Shatilo, VB, 2012) |
| "This systematic review and meta-analysis of randomized controlled trials (RCTs) was carried out to determine the effect of melatonin supplementation on the inflammatory markers among individuals with metabolic syndrome (MetS) and related disorders." | 4.98 | The effects of melatonin supplementation on inflammatory markers among patients with metabolic syndrome or related disorders: a systematic review and meta-analysis of randomized controlled trials. ( Akbari, M; Amirani, E; Asemi, Z; Heydari, ST; Lankarani, KB; Ostadmohammadi, V; Reiter, RJ; Tabrizi, R, 2018) |
| " There has also been a marked increase in the prevalence of metabolic syndrome in recent decades, which has been associated with a reduction in nocturnal pineal production of melatonin with aging and an increased risk of coronary diseases, type 2 diabetes mellitus (T2DM) and death." | 4.90 | Melatonin and metabolic regulation: a review. ( A-Serrano, MM; Acuña-Castroviejo, D; Agil, A; Blanca-Herrera, RM; Fernández-Vázquez, G; Navarro-Alarcón, M; Ruiz-Ojeda, FJ, 2014) |
| "Sprague-Dawley rats were divided into control (n = 8), melatonin (n = 8), metabolic syndrome (n = 8) and metabolic syndrome + melatonin (n = 8) groups." | 4.02 | Melatonin ameliorates cardiac remodelling in fructose-induced metabolic syndrome rat model by using genes encoding cardiac potassium ion channels. ( Ovali, MA; Oztopuz, O; Vardar, SA, 2021) |
| " Melatonin, which transmits information to regulate the sleep-wake rhythm and other such biorhythms, has been implicated in insulin resistance, antioxidant behaviors, and metabolic syndrome." | 3.83 | Salivary melatonin levels and sleep-wake rhythms in pregnant women with hypertensive and glucose metabolic disorders: A prospective analysis. ( Hayase, M; Samejima, M; Seki, H; Shimada, M; Shirai, F, 2016) |
| "The objective of this study was to evaluate the efficacy of melatonin to affect mild inflammation in the metabolic syndrome (MS) induced by a high-fat diet in rats." | 3.80 | Melatonin normalizes clinical and biochemical parameters of mild inflammation in diet-induced metabolic syndrome in rats. ( Cano Barquilla, P; Cardinali, DP; Esquifino, AI; Fernández-Mateos, P; Jiménez-Ortega, V; Pagano, ES, 2014) |
| "Effect of light regimens (standard 12:12 light/dark, constant light, natural lightning of the north-west of Russia) and that of melatonin on the development of metabolic syndrome during aging of rats was studied." | 3.79 | Melatonin prevents the development of the metabolic syndrome in male rats exposed to different light/dark regimens. ( Anisimov, V; Vinogradova, I, 2013) |
| "The aim of this study was to investigate the effects of melatonin on glucose homeostasis in young male Zucker diabetic fatty (ZDF) rats, an experimental model of metabolic syndrome and type 2 diabetes mellitus (T2DM)." | 3.78 | Melatonin improves glucose homeostasis in young Zucker diabetic fatty rats. ( Agil, A; Fernández-Vázquez, G; Figueroa, A; Rosado, I; Ruiz, R; Zen, N, 2012) |
| "In this study, we examined whether melatonin improves metabolic syndrome induced by high fructose intake in male Wistar rats." | 3.78 | Melatonin improves metabolic syndrome induced by high fructose intake in rats. ( Kitagawa, A; Ohashi, K; Ohta, Y, 2012) |
| " The patients presenting with metabolic syndrome are characterized by the interrelation between melatonin hypersecretion, parameters of hyperactivity of the sympathetic component of the nervous system, and prognostically unfavourable variants of cardiac and vascular remodeling (including endothelial dysfunction, concentric remodeling and concentric myocardial ventricular hypertrophy)." | 3.78 | [Melatonin as a marker of intensity of structural and functional changes in the heart and vessels of the patients presenting with metabolic syndrome]. ( Balliuzek, MF; Grinenko, TN; Kvetnaia, TV, 2012) |
| "Melatonin, leptin, and insulin secretion was studied in 25 men with metabolic syndrome (MS) verified against IDF criteria (2005) (mean age 44 +/- 2 yr)." | 3.77 | [Relationship between insulin, leptin, and melatonin contents in patients with metabolic syndrome]. ( , 2011) |
| "The level of 6-oxymelatonin sulfate, the main metabolite of melatonin (MT), in morning urine samples from patients with metabolic syndrome (MS) suggests enhanced MT production at night." | 3.75 | [The role of melatonin in the development of metabolic syndrome]. ( Balliuzek, MF; Grinenko, TN; Kvetnaia, TV, 2009) |
| "Melatonin secretion decreased in fructose fed rats that developed hypertension." | 3.74 | The role of melatonin in the pathogenesis of hypertension in rats with metabolic syndrome. ( Grossman, E; Leibowitz, A; Peleg, E; Shabtai, Z; Shamiss, A; Sharabi, Y, 2008) |
| "During two years the influence of light regimens (standard lightning--LD, constant lightning--LL, natural lightning of the North-West of Russia--NL) and of melatonin on the development of metabolic syndrome of ageing LIO rats was studied." | 3.74 | [Effect of different light regimens on the development of metabolic syndrome of aging rats]. ( Vinogradova, IA, 2007) |
| "The interrelations between testosterone, insulin and melatonin levels in males with metabolic syndrome (MS) are still not clarified, especially in young age groups." | 3.73 | Low testosterone levels and unimpaired melatonin secretion in young males with metabolic syndrome. ( Kirilov, G; Kumanov, P; Robeva, R; Tomova, A, 2006) |
| "Melatonin was beneficial in lowering blood pressure among bipolar disorder patients; this blood pressure-lowering effect was not prominent among schizophrenic patients." | 2.53 | The role of melatonin and melatonin agonists in counteracting antipsychotic-induced metabolic side effects: a systematic review. ( Bahk, WM; Wang, HR; Woo, YS, 2016) |
| "Obesity is associated with an oxidative stress status, defined as an excessive production of reactive oxygen species (ROS) compared to the level of antioxidants acting in the natural defence systems." | 2.50 | Obesity and oxidative stress: potential roles of melatonin as antioxidant and metabolic regulator. ( Bonnefont-Rousselot, D, 2014) |
| "Melatonin has specific MT1 and MT2 receptors localized in all body cells." | 2.49 | [Metabolic syndrome and melatonin]. ( Burlakova, OV; Golichenkov, VA; Molchanov, AIu; Rapoport, SI; Savchenko, ES; Suprunenko, ES, 2013) |
| "Melatonin has been suggested to be effective in improving MetS through its anti-hyperlipidemic action." | 2.49 | Metabolic syndrome, its pathophysiology and the role of melatonin. ( Espino, J; Mohamed, M; Ohta, Y; Pariente, JA; Rodriguez, AB; Srinivasan, V; Zakaria, R, 2013) |
| "Obesity has become an epidemic in industrialized and developing countries." | 2.48 | Obesity and metabolic syndrome: association with chronodisruption, sleep deprivation, and melatonin suppression. ( Korkmaz, A; Ma, S; Reiter, RJ; Tan, DX, 2012) |
| "Melatonin has been shown to have beneficial effects in cardiovascular disorders including ischaemic heart disease and hypertension." | 2.48 | Melatonin and the metabolic syndrome: a tool for effective therapy in obesity-associated abnormalities? ( du Toit, EF; Lochner, A; Nduhirabandi, F, 2012) |
| " The recognition of the periodicity of biological processes makes the optimal dosing of certain drugs feasible." | 2.48 | [Physiological and pathophysiological role of the circadian clock system]. ( Halmos, T; Suba, I, 2012) |
| "Melatonin is an effective chronobiotic agent able to change the phase and amplitude of circadian rhythms." | 2.47 | Melatonin and the metabolic syndrome: physiopathologic and therapeutical implications. ( Cano, P; Cardinali, DP; Esquifino, AI; Jiménez-Ortega, V, 2011) |
| "Metabolic syndrome was induced in rats by 20% (w/v) fructose solution in tap water, and melatonin was administered at the dose of 20 mg/kg bw per day by oral gavage." | 1.42 | Beneficial effects of melatonin on serum nitric oxide, homocysteine, and ADMA levels in fructose-fed rats. ( Bircan, FS; Kantar, Ş; Paşaoğlu, ÖT; Türközkan, N, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (12.77) | 29.6817 |
| 2010's | 35 (74.47) | 24.3611 |
| 2020's | 6 (12.77) | 2.80 |
| Authors | Studies |
|---|---|
| Miola, A | 1 |
| Fornaro, M | 1 |
| Sambataro, F | 1 |
| Solmi, M | 1 |
| Campos, LA | 1 |
| Baltatu, OC | 1 |
| Senar, S | 1 |
| Ghimouz, R | 1 |
| Alefishat, E | 1 |
| Cipolla-Neto, J | 1 |
| Bijnens, S | 1 |
| Depoortere, I | 1 |
| Cheng, WY | 1 |
| Lam, KL | 1 |
| Li, X | 1 |
| Kong, AP | 1 |
| Cheung, PC | 1 |
| Romo-Nava, F | 1 |
| Buijs, RM | 1 |
| McElroy, SL | 1 |
| Ovali, MA | 1 |
| Oztopuz, O | 1 |
| Vardar, SA | 1 |
| Cardinali, DP | 4 |
| Vigo, DE | 1 |
| Al-Sarraf, IAK | 1 |
| Kasabri, V | 1 |
| Akour, A | 1 |
| Naffa, R | 1 |
| Akbari, M | 2 |
| Ostadmohammadi, V | 2 |
| Tabrizi, R | 2 |
| Lankarani, KB | 2 |
| Heydari, ST | 1 |
| Amirani, E | 1 |
| Reiter, RJ | 3 |
| Asemi, Z | 2 |
| Santamaría, R | 1 |
| Díaz-Tocados, JM | 1 |
| Pendón-Ruiz de Mier, MV | 1 |
| Robles, A | 1 |
| Salmerón-Rodríguez, MD | 1 |
| Ruiz, E | 1 |
| Vergara, N | 1 |
| Aguilera-Tejero, E | 1 |
| Raya, A | 1 |
| Ortega, R | 1 |
| Felsenfeld, A | 1 |
| Muñoz-Castañeda, JR | 1 |
| Martín-Malo, A | 1 |
| Aljama, P | 1 |
| Rodríguez, M | 1 |
| Mirhosseini, N | 1 |
| Keshtkaran, Z | 1 |
| Diez, ER | 1 |
| Renna, NF | 1 |
| Prado, NJ | 1 |
| Lembo, C | 1 |
| Ponce Zumino, AZ | 1 |
| Vazquez-Prieto, M | 1 |
| Miatello, RM | 1 |
| Vinogradova, I | 1 |
| Anisimov, V | 1 |
| Hardeland, R | 2 |
| Gamble, KL | 1 |
| Berry, R | 1 |
| Frank, SJ | 1 |
| Young, ME | 1 |
| Bonnefont-Rousselot, D | 1 |
| Corbalán-Tutau, MD | 1 |
| Gómez-Abellán, P | 1 |
| Madrid, JA | 1 |
| Canteras, M | 1 |
| Ordovás, JM | 1 |
| Garaulet, M | 1 |
| Cano Barquilla, P | 1 |
| Pagano, ES | 1 |
| Jiménez-Ortega, V | 2 |
| Fernández-Mateos, P | 1 |
| Esquifino, AI | 2 |
| Navarro-Alarcón, M | 1 |
| Ruiz-Ojeda, FJ | 1 |
| Blanca-Herrera, RM | 1 |
| A-Serrano, MM | 1 |
| Acuña-Castroviejo, D | 1 |
| Fernández-Vázquez, G | 2 |
| Agil, A | 2 |
| Boivin, DB | 1 |
| Boudreau, P | 1 |
| Kantar, Ş | 2 |
| Türközkan, N | 2 |
| Bircan, FS | 2 |
| Paşaoğlu, ÖT | 2 |
| Rapoport, SI | 3 |
| Molchanov, AIu | 1 |
| Golichenkov, VA | 1 |
| Burlakova, OV | 1 |
| Suprunenko, ES | 1 |
| Savchenko, ES | 1 |
| Demirtas, CY | 1 |
| Shimada, M | 1 |
| Seki, H | 1 |
| Samejima, M | 1 |
| Hayase, M | 1 |
| Shirai, F | 1 |
| Wang, HR | 1 |
| Woo, YS | 1 |
| Bahk, WM | 1 |
| Klimentova, J | 1 |
| Cebova, M | 1 |
| Barta, A | 1 |
| Matuskova, Z | 1 |
| Vrankova, S | 1 |
| Rehakova, R | 1 |
| Kovacsova, M | 1 |
| Pechanova, O | 1 |
| Mühlbauer, E | 1 |
| Gross, E | 1 |
| Labucay, K | 1 |
| Wolgast, S | 1 |
| Peschke, E | 1 |
| Balliuzek, MF | 2 |
| Grinenko, TN | 2 |
| Kvetnaia, TV | 2 |
| Koziróg, M | 1 |
| Poliwczak, AR | 1 |
| Duchnowicz, P | 1 |
| Koter-Michalak, M | 1 |
| Sikora, J | 1 |
| Broncel, M | 1 |
| Cano, P | 1 |
| Tan, DX | 1 |
| Korkmaz, A | 1 |
| Ma, S | 1 |
| Rosado, I | 1 |
| Ruiz, R | 1 |
| Figueroa, A | 1 |
| Zen, N | 1 |
| Kitagawa, A | 1 |
| Ohta, Y | 2 |
| Ohashi, K | 1 |
| Nduhirabandi, F | 1 |
| du Toit, EF | 1 |
| Lochner, A | 1 |
| Shatilo, VB | 1 |
| Bondarenko, EV | 1 |
| Antoniuk-Shcheglova, IA | 1 |
| Halmos, T | 1 |
| Suba, I | 1 |
| Srinivasan, V | 1 |
| Espino, J | 1 |
| Pariente, JA | 1 |
| Rodriguez, AB | 1 |
| Mohamed, M | 1 |
| Zakaria, R | 1 |
| Ma, N | 1 |
| Hardy, DB | 1 |
| Dzherieva, iS | 2 |
| Volkova, NI | 2 |
| Robeva, R | 2 |
| Kirilov, G | 2 |
| Tomova, A | 2 |
| Kumanov, P | 2 |
| Leibowitz, A | 1 |
| Peleg, E | 1 |
| Sharabi, Y | 1 |
| Shabtai, Z | 1 |
| Shamiss, A | 1 |
| Grossman, E | 1 |
| Vinogradova, IA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Meal Timing, Genetics and Weight Loss in a Mediterranean Population[NCT02829619] | 5,788 participants (Anticipated) | Observational | 2008-01-31 | Recruiting | |||
| A Triple Blinded Randomized Controlled Trial of Oral Melatonin in Elevated Blood Pressure Individual (MRCTEBP)[NCT03764020] | Phase 3 | 320 participants (Anticipated) | Interventional | 2019-06-01 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
21 reviews available for melatonin and Metabolic Syndrome
| Article | Year |
|---|---|
Melatonin and melatonin-agonists for metabolic syndrome components in patients treated with antipsychotics: A systematic review and meta-analysis.
Topics: Antipsychotic Agents; Bipolar Disorder; Humans; Melatonin; Metabolic Syndrome; Randomized Controlled | 2022 |
Controlled light exposure and intermittent fasting as treatment strategies for metabolic syndrome and gut microbiome dysregulation in night shift workers.
Topics: Animals; Circadian Rhythm; Gastrointestinal Microbiome; Humans; Intermittent Fasting; Light; Mammals | 2023 |
The use of melatonin to mitigate the adverse metabolic side effects of antipsychotics.
Topics: Antipsychotic Agents; Humans; Melatonin; Mental Disorders; Metabolic Syndrome | 2021 |
Melatonin, mitochondria, and the metabolic syndrome.
Topics: Animals; Antioxidants; Humans; Melatonin; Metabolic Syndrome; Mitochondria | 2017 |
The effects of melatonin supplementation on inflammatory markers among patients with metabolic syndrome or related disorders: a systematic review and meta-analysis of randomized controlled trials.
Topics: Biomarkers; C-Reactive Protein; Dietary Supplements; Humans; Inflammation; Interleukin-6; Melatonin; | 2018 |
The effects of melatonin supplementation on blood pressure in patients with metabolic disorders: a systematic review and meta-analysis of randomized controlled trials.
Topics: Blood Pressure; Central Nervous System Depressants; Dietary Supplements; Humans; Melatonin; Metaboli | 2019 |
Melatonin and the theories of aging: a critical appraisal of melatonin's role in antiaging mechanisms.
Topics: Aging; Animals; Cellular Senescence; Free Radicals; Humans; Melatonin; Metabolic Syndrome; Models, B | 2013 |
Circadian clock control of endocrine factors.
Topics: Adiponectin; Adult; Animals; Child; Circadian Clocks; Circadian Rhythm; Endocrine System; Female; Ho | 2014 |
Obesity and oxidative stress: potential roles of melatonin as antioxidant and metabolic regulator.
Topics: Animals; Antioxidants; Humans; Melatonin; Metabolic Syndrome; Obesity; Oxidative Stress; Reactive Ox | 2014 |
Melatonin and metabolic regulation: a review.
Topics: Animals; Blood Pressure; Diabetes Mellitus, Type 2; Disease Models, Animal; Humans; Hyperglycemia; M | 2014 |
Impacts of shift work on sleep and circadian rhythms.
Topics: Accidents; Arousal; Automobile Driving; Cardiovascular Diseases; Circadian Rhythm; Circadian Rhythm | 2014 |
[Metabolic syndrome and melatonin].
Topics: Humans; Melatonin; Metabolic Syndrome | 2013 |
Inflammaging, Metabolic Syndrome and Melatonin: A Call for Treatment Studies.
Topics: Aging; Animals; Humans; Inflammation Mediators; Melatonin; Metabolic Syndrome; Models, Biological; O | 2017 |
The role of melatonin and melatonin agonists in counteracting antipsychotic-induced metabolic side effects: a systematic review.
Topics: Antioxidants; Antipsychotic Agents; Humans; Indenes; Melatonin; Metabolic Syndrome; Randomized Contr | 2016 |
Melatonin and the metabolic syndrome: physiopathologic and therapeutical implications.
Topics: Animals; Central Nervous System Depressants; Circadian Rhythm; Humans; Melatonin; Metabolic Syndrome | 2011 |
Obesity and metabolic syndrome: association with chronodisruption, sleep deprivation, and melatonin suppression.
Topics: Adolescent; Adult; Animals; Child; Chronobiology Disorders; Comorbidity; Disease Models, Animal; Hum | 2012 |
Melatonin and the metabolic syndrome: a tool for effective therapy in obesity-associated abnormalities?
Topics: Body Weight; Energy Metabolism; Humans; Insulin Resistance; Melatonin; Metabolic Syndrome; Obesity | 2012 |
[Physiological and pathophysiological role of the circadian clock system].
Topics: Aging; ARNTL Transcription Factors; Blood Coagulation Disorders; Cardiovascular Diseases; Circadian | 2012 |
Metabolic syndrome, its pathophysiology and the role of melatonin.
Topics: Animals; Antioxidants; Dyslipidemias; Humans; Insulin Resistance; Melatonin; Metabolic Syndrome; Pat | 2013 |
The fetal origins of the metabolic syndrome: can we intervene?
Topics: Antioxidants; Ascorbic Acid; Diet Therapy; Dietary Supplements; Exenatide; Fatty Acids, Omega-3; Fem | 2012 |
[Melatonin and metabolic syndrome: is there an association?].
Topics: Humans; Melatonin; Metabolic Syndrome | 2012 |
2 trials available for melatonin and Metabolic Syndrome
| Article | Year |
|---|---|
Melatonin treatment improves blood pressure, lipid profile, and parameters of oxidative stress in patients with metabolic syndrome.
Topics: Blood Pressure; Catalase; Cholesterol, LDL; Glutathione Peroxidase; Humans; Lipids; Melatonin; Metab | 2011 |
[Metabolic disorders in elderly patients with hypertension and their correction with melatonin].
Topics: Aged; Antihypertensive Agents; Blood Glucose; Body Mass Index; Carbohydrate Metabolism; Drug Therapy | 2012 |
24 other studies available for melatonin and Metabolic Syndrome
| Article | Year |
|---|---|
Multiplatform-Integrated Identification of Melatonin Targets for a Triad of Psychosocial-Sleep/Circadian-Cardiometabolic Disorders.
Topics: Animals; Circadian Rhythm; Melatonin; Metabolic Syndrome; Molecular Targeted Therapy; Receptors, Mel | 2023 |
Circadian disruption-induced metabolic syndrome in mice is ameliorated by oat β-glucan mediated by gut microbiota.
Topics: Animals; Avena; beta-Glucans; Cichorium intybus; Circadian Rhythm; Gastrointestinal Microbiome; Inul | 2021 |
Melatonin ameliorates cardiac remodelling in fructose-induced metabolic syndrome rat model by using genes encoding cardiac potassium ion channels.
Topics: Action Potentials; Animals; Female; Fructose; Heart; Heart Ventricles; Long QT Syndrome; Male; Melat | 2021 |
Melatonin and cryptochrome 2 in metabolic syndrome patients with or without diabetes: a cross-sectional study.
Topics: Adiposity; Adult; Blood Pressure; Cross-Sectional Studies; Cryptochromes; Diabetes Mellitus, Type 2; | 2018 |
Increased Phosphaturia Accelerates The Decline in Renal Function: A Search for Mechanisms.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Animals; Antioxidants; Cell Line; Female; Glomerular Fil | 2018 |
Melatonin, given at the time of reperfusion, prevents ventricular arrhythmias in isolated hearts from fructose-fed rats and spontaneously hypertensive rats.
Topics: Animals; Antioxidants; Disease Models, Animal; Drug Evaluation, Preclinical; Fructose; Hypertension; | 2013 |
Melatonin prevents the development of the metabolic syndrome in male rats exposed to different light/dark regimens.
Topics: Animals; Blood Glucose; C-Peptide; Circadian Rhythm; Darkness; Light; Male; Melatonin; Metabolic Syn | 2013 |
Toward a chronobiological characterization of obesity and metabolic syndrome in clinical practice.
Topics: Adiponectin; Adult; Biomarkers; Blood Glucose; Body Mass Index; Cholesterol, HDL; Cholesterol, LDL; | 2015 |
Melatonin normalizes clinical and biochemical parameters of mild inflammation in diet-induced metabolic syndrome in rats.
Topics: Animals; Inflammation; Male; Melatonin; Metabolic Syndrome; Rats; Rats, Wistar | 2014 |
Beneficial effects of melatonin on serum nitric oxide, homocysteine, and ADMA levels in fructose-fed rats.
Topics: Animals; Arginine; Biomarkers; Fructose; Homocysteine; Male; Melatonin; Metabolic Syndrome; Nitric O | 2015 |
The investigation of melatonin effect on liver antioxidant and oxidant levels in fructose-mediated metabolic syndrome model.
Topics: Animals; Antioxidants; Disease Models, Animal; Fructose; Insulin Resistance; Liver; Male; Melatonin; | 2015 |
Salivary melatonin levels and sleep-wake rhythms in pregnant women with hypertensive and glucose metabolic disorders: A prospective analysis.
Topics: Adult; Circadian Rhythm; Demography; Female; Glucose; Humans; Hypertension, Pregnancy-Induced; Melat | 2016 |
Effect of melatonin on blood pressure and nitric oxide generation in rats with metabolic syndrome.
Topics: Animals; Blood Pressure; Brain; Enzyme Activation; Hypertension; Male; Melatonin; Metabolic Syndrome | 2016 |
Loss of melatonin signalling and its impact on circadian rhythms in mouse organs regulating blood glucose.
Topics: Animals; Blood Glucose; Circadian Rhythm; Gene Expression Regulation; Insulin; Insulin Secretion; In | 2009 |
[The role of melatonin in the development of metabolic syndrome].
Topics: Aged; Aged, 80 and over; Aging; Circadian Rhythm; Disease Progression; Female; Humans; Male; Melaton | 2009 |
Melatonin improves glucose homeostasis in young Zucker diabetic fatty rats.
Topics: Animals; Antioxidants; Diabetes Mellitus, Type 2; Disease Models, Animal; Fatty Acids, Nonesterified | 2012 |
Melatonin improves metabolic syndrome induced by high fructose intake in rats.
Topics: Adipokines; Analysis of Variance; Animals; Antioxidants; Blood Glucose; Body Weight; Cholesterol; Di | 2012 |
[Relationship between insulin, leptin, and melatonin contents in patients with metabolic syndrome].
Topics: Adult; Blood Glucose; Down-Regulation; Humans; Insulin; Insulin Secretion; Leptin; Male; Melatonin; | 2011 |
[Melatonin as a marker of intensity of structural and functional changes in the heart and vessels of the patients presenting with metabolic syndrome].
Topics: Aged; Aged, 80 and over; Biomarkers; Blood Vessels; Female; Humans; Male; Melatonin; Metabolic Syndr | 2012 |
[Melatonin as a regulator of metabolism].
Topics: Adult; Blood Glucose; Humans; Insulin; Lipoproteins, LDL; Male; Melatonin; Metabolic Syndrome; Middl | 2012 |
Low testosterone levels and unimpaired melatonin secretion in young males with metabolic syndrome.
Topics: Adult; Age Factors; Case-Control Studies; Humans; Hyperinsulinism; Insulin; Luteinizing Hormone; Mal | 2006 |
Melatonin-insulin interactions in patients with metabolic syndrome.
Topics: Adult; Case-Control Studies; Circadian Rhythm; Female; Humans; Insulin; Lipids; Male; Melatonin; Met | 2008 |
The role of melatonin in the pathogenesis of hypertension in rats with metabolic syndrome.
Topics: Animals; Blood Pressure; Body Weight; Dietary Sucrose; Dietary Supplements; Disease Models, Animal; | 2008 |
[Effect of different light regimens on the development of metabolic syndrome of aging rats].
Topics: Aging; Animals; Antioxidants; Blood Glucose; Cholesterol; Eating; Insulin Resistance; Light; Lipopro | 2007 |